| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| RFS/DFS | 0.30 [0.17, 0.52] | | < 1 | | 23% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
safety endpoints 00 |
| AE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 18.39 [5.56, 60.77] | | < 1 | | 47% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 19.58 [4.47, 85.82] | | < 1 | | 45% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 4.08 [2.31, 7.19] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| SAE (grade 3-4) | 5.29 [2.15, 13.00] | | < 1 | | 53% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 12.43 [2.18, 70.81] | | < 1 | | 76% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 14.97 [0.88, 254.99] | | < 1 | | 74% | 2 studies (2/-) | 3.2 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 10.70 [2.57, 44.58] | | < 1 | | 41% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 14.96 [2.66, 84.03] | | < 1 | | 80% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 24.36 [3.72, 159.46] | | < 1 | | 65% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 24.18 [2.93, 199.61] | | < 1 | | 55% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.41 [0.04, 4.76] | | < 1 | | 0% | 2 studies (2/-) | 76.0 % | low | not evaluable | high | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 1.44 [0.11, 19.02] | | < 1 | | 0% | 2 studies (2/-) | 39.2 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 6.11 [0.72, 51.62] | | < 1 | | 0% | 2 studies (2/-) | 4.9 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.30 [0.15, 11.32] | | < 1 | | 0% | 2 studies (2/-) | 40.7 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Ear and labyrinth disorders TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 6.83 [1.19, 39.30] | | < 1 | | 0% | 2 studies (2/-) | 1.6 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Gastritis TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 11.58 [2.10, 63.74] | | < 1 | | 0% | 2 studies (2/-) | 0.3 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.55 [1.09, 19.08] | | < 1 | | 0% | 2 studies (2/-) | 1.9 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 10.17 [2.60, 39.71] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Hypertension TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 6.11 [0.72, 51.62] | | < 1 | | 0% | 2 studies (2/-) | 4.9 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 4.46 [1.07, 18.60] | | < 1 | | 12% | 2 studies (2/-) | 2.0 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 8.10 [1.94, 33.82] | | < 1 | | 15% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.86 [1.07, 7.62] | | < 1 | | 0% | 2 studies (2/-) | 1.8 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.30 [0.15, 11.32] | | < 1 | | 0% | 2 studies (2/-) | 40.7 % | low | not evaluable | high | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.31 [0.03, 3.39] | | < 1 | | 0% | 2 studies (2/-) | 83.0 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
| Myositis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 0.78 [0.11, 5.64] | | < 1 | | 0% | 2 studies (2/-) | 59.7 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 3.96 [0.64, 24.63] | | < 1 | | 0% | 2 studies (2/-) | 7.1 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
